PT-141 nasal spray is Rebody's fastest needle-free bremelanotide route. Early intranasal studies show that bremelanotide can produce measurable effects through the nasal route. The strongest modern efficacy and safety evidence belongs to the FDA-approved 1.75 mg subcutaneous injection, not this compounded bottle.
The spray's case is speed, privacy, and needle avoidance. Keep its formulation, dose, and outcomes separate from Vyleesi.
The short answer
PT-141 is another name used for bremelanotide. It acts at melanocortin receptors involved in central sexual-response pathways.
Rebody's nasal product is compounded at 5 mg/mL in a 5 mL bottle. Current directions describe use before anticipated sexual activity, with limits on repeat use. The final label controls the number of sprays, timing, priming, storage, and maximum use.
Current product at a glance
| Fact | Rebody PT-141 nasal spray |
|---|---|
| Active | Bremelanotide, also called PT-141 |
| Form | Nasal spray |
| Concentration | 5 mg/mL |
| Bottle | 5 mL |
| Published timing | At least 30 to 60 minutes before anticipated sexual activity |
| Use directions | Follow the prescription label |
| Package price | $199 |
Concentration is not the amount in one spray. Use the metered output and priming directions on the pharmacy label.
What PT-141 targets
Bremelanotide works through melanocortin signaling rather than the blood-flow pathway used by sildenafil or tadalafil. This places it in the desire and arousal conversation.
Desire, genital arousal, lubrication, erection firmness, orgasm, pain, relationship distress, and hormone status are different problems. One product should not be expected to solve all of them.
What is FDA approved
FDA approved Vyleesi as a 1.75 mg subcutaneous injection for acquired, generalized hypoactive sexual desire disorder in premenopausal women when low desire causes marked distress and is not due to another condition, relationship problem, or medication effect.
That approval does not extend to compounded nasal spray, men, every type of low desire, or a different dose. Rebody's spray is not Vyleesi.
What early intranasal studies found
A small crossover study gave a single 20 mg intranasal dose to 18 premenopausal women with female sexual arousal disorder. More participants reported moderate or high desire after bremelanotide than placebo. The study was preliminary, used one specific research dose, and did not test Rebody's bottle.
An early trial in healthy men and men with mild-to-moderate erectile dysfunction measured pharmacokinetics and erectile response after intranasal PT-141. It reported dose-related exposure and common nausea and flushing. It was a small early-development study, not a modern pivotal trial for the current product.
These studies support nasal-route plausibility. They do not create a dose conversion or guarantee a result.
Nasal spray vs approved injection
Nasal spray avoids needles and takes seconds to use. Injection has the deeper evidence base, a defined FDA-approved dose, and a detailed prescribing label for its approved population.
The routes differ in absorption, peak exposure, variability, adverse effects, and timing. Do not use the injection label to calculate sprays. Do not use an early research dose as a home instruction.
Nasal spray vs troche
Spray wins on administration speed. Troche wins when congestion, nosebleeds, irritation, or dislike of nasal dosing is the main barrier.
Neither compounded route has a head-to-head outcome trial. The troche adds dissolve time and has less route-specific human evidence. The spray adds pump technique and nasal tolerance.
Technique and timing
Use the bottle only as the pharmacy directs. Prime it when instructed. Use the stated nostril, head position, and timing. Avoid adding sprays because the first one leaked or was hard to feel.
Record congestion, drainage, taste, irritation, nausea, flushing, headache, and the actual interval before sexual activity. Technique errors and timing can look like treatment failure.
Read the bottle without guessing the dose
The current product is 5 mg/mL in a 5 mL bottle. At 0.1 mL per metered spray, each spray delivers 0.5 mg. Bottle volume, concentration, sprays per use, and maximum use are separate facts.
The current direction starts with one spray in each nostril, for two sprays and 1 mg total. If tolerated, subsequent administrations can use two sprays in each nostril, for four sprays and 2 mg total. Do not exceed 2 mg per administration or eight administrations per month. Follow the pharmacy label for priming and technique.
Nasal technique can change the experience. Congestion, spray angle, forceful sniffing, drainage, and a dirty nozzle can make the routine inconsistent. Record the administered sprays and the response instead of repeating a dose because the first attempt felt uncertain.
Use the early nasal studies for the right question
The early intranasal studies matter because they tested bremelanotide through the same broad route. One small study in premenopausal women with sexual arousal disorder evaluated a 20 mg intranasal dose in a controlled setting. Another early study included healthy men and men with mild-to-moderate erectile dysfunction and measured pharmacokinetics and erectile response across intranasal doses.
These studies establish more than a theoretical mechanism. Researchers administered intranasal bremelanotide and measured human responses. They do not establish the outcome, dose, or safety profile of the current 5 mg/mL compounded bottle. The finished device still needs its own evidence.
Define success before an as-needed trial
Desire, arousal, genital response, erection quality, distress, and sexual satisfaction are related but different outcomes. Choose the one that created the treatment question. A product can change one dimension without fixing the whole experience.
Record dose time, anticipated activity time, nausea, flushing, headache, nasal irritation, and the selected outcome. Include alcohol, a large meal, relationship stress, and other sexual-health medicines because they can change the night. Several rushed attempts with different doses reveal less than a small number of well-recorded uses.
If the response is absent, inconsistent, or limited by side effects, bring the record to the prescriber instead of changing the directions yourself.
Blood pressure and nausea matter
The approved injection label warns about transient blood-pressure increases and heart-rate decreases. It is contraindicated in uncontrolled hypertension or known cardiovascular disease. Nausea is common with approved injection use.
Those warnings deserve clinician review for a compounded route too. The nasal spray has its own exposure profile, but a different route does not erase the molecule's safety questions.
Seek urgent help for chest pain, severe headache, fainting, breathing difficulty, facial or tongue swelling, or another severe reaction. Persistent focal skin darkening and severe nausea also need clinical guidance.
What to review before choosing another package
Count completed attempts, not calendar days. For each use, record the number of prescribed sprays, the interval before activity, the selected sexual-response outcome, and any side effects. This separates a product that was never used under workable conditions from one that produced a consistent poor response.
Review nasal tolerance as its own result. A bottle can be fast and private yet fail as a routine because of congestion, burning, drainage, or nosebleeds. The troche may become the stronger practical option when the nose is the barrier, even though its route-specific evidence is thinner.
Keep blood pressure history and other sexual-health medicines visible. Sildenafil, tadalafil, hormone treatment, antidepressants, alcohol, and relationship conditions can alter the experience or the safety discussion. Do not combine products or shorten the interval without the prescriber.
Finally, compare the complete $199 package. Confirm 5 mg/mL, the 5 mL fill, metered output, maximum use, shipping, storage, and refill terms. A cheaper bottle with a different pump or concentration is not the same offer.
If the bottle delivered a reliable response but the pump was difficult to use, solve the device question separately from the molecule question. If the pump worked well but nausea or blood-pressure symptoms limited use, changing to another compounded route may not remove the underlying concern. That distinction gives the prescriber a clearer next decision.
Questions people ask
Is PT-141 nasal spray FDA approved?
No. Vyleesi is the FDA-approved subcutaneous bremelanotide product. A compounded nasal spray is a different finished product and route.
Does PT-141 nasal spray work for women?
One small early intranasal study in 18 premenopausal women found subjective signals. It does not establish the outcome of Rebody's bottle.
Does it work for men?
Early intranasal studies measured erectile response in men. Male use remains outside the Vyleesi indication, and the current spray has not been proven as an ED treatment.
How fast does it work?
Current Rebody directions place use at least 30 to 60 minutes before anticipated sexual activity. Individual response can differ. Follow the label.
How much does it cost?
The current package price is $199. Confirm bottle size, metered output, prescribed use, shipping, storage, and refill terms.
Bottom line
PT-141 nasal spray is the practical route for fast, private, needle-free administration. Early nasal studies make the route credible enough to investigate. The approved injection still owns the strongest efficacy, dosing, and safety evidence.